Alternaturals Inc
Alternaturals, Inc. manufactures and distributes supplements and all-natural remedies that are alternatives to prescription drugs. Its products include Focamine, an all-natural focus, attention, and concentration promoter for people suffering from ADHD; and Sombium, an alternative sleep aid. The company was formerly known as Zhong Nong Yuan Fang Holdings, Inc. and changed its name to Alternatural… Read more
Alternaturals Inc (ANAS) - Net Assets
Latest net assets as of March 2025: $3.27K USD
Based on the latest financial reports, Alternaturals Inc (ANAS) has net assets worth $3.27K USD as of March 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($58.71K) and total liabilities ($55.45K). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $3.27K |
| % of Total Assets | 5.56% |
| Annual Growth Rate | -14.76% |
| 5-Year Change | -99.49% |
| 10-Year Change | N/A |
| Growth Volatility | 111.9 |
Alternaturals Inc - Net Assets Trend (1998–2024)
This chart illustrates how Alternaturals Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Alternaturals Inc (1998–2024)
The table below shows the annual net assets of Alternaturals Inc from 1998 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $7.77K | -56.81% |
| 2023-12-31 | $17.98K | -67.33% |
| 2014-12-31 | $55.05K | -97.60% |
| 2000-12-31 | $2.29 Million | +51.12% |
| 1999-12-31 | $1.52 Million | +207.30% |
| 1998-12-31 | $493.29K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Alternaturals Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 58507800.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $1.04K | 13.42% |
| Other Comprehensive Income | $6.00 | 0.08% |
| Other Components | $686.49K | 8838.51% |
| Total Equity | $7.77K | 100.00% |
Alternaturals Inc Competitors by Market Cap
The table below lists competitors of Alternaturals Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
British Smaller Companies Vct 2 Plc
LSE:BSC
|
$59.25 |
|
Milton Capital PLC
LSE:MII
|
$59.27 |
|
HORDS LTD.
GSE:HORDS
|
$59.49 |
|
Verianos SE
STU:VROS
|
$59.69 |
|
Caduceus Software Systems Corp
PINK:CSOC
|
$59.16 |
|
Araneta Properties Inc
PSE:ARA
|
$59.09 |
|
Cardax Inc
PINK:CDXI
|
$59.02 |
|
City and Land Developers Inc
PSE:LAND
|
$58.76 |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Alternaturals Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 17,983 to 7,767, a change of -10,216 (-56.8%).
- Net loss of 10,216 reduced equity.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-10.22K | -131.53% |
| Total Change | $- | -56.81% |
Book Value vs Market Value Analysis
This analysis compares Alternaturals Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 87.24x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1998-12-31 | $0.00 | $0.01 | x |
| 1999-12-31 | $0.00 | $0.01 | x |
| 2000-12-31 | $0.00 | $0.01 | x |
| 2014-12-31 | $0.00 | $0.01 | x |
| 2019-12-31 | $0.00 | $0.01 | x |
| 2020-12-31 | $0.00 | $0.01 | x |
| 2021-12-31 | $0.00 | $0.01 | x |
| 2022-12-31 | $0.00 | $0.01 | x |
| 2023-12-31 | $0.00 | $0.01 | x |
| 2024-12-31 | $0.00 | $0.01 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Alternaturals Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -131.53%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 7.56x
- Recent ROE (-131.53%) is above the historical average (-279.40%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1998 | -19.37% | -78.82% | 0.17x | 1.41x | $-144.86K |
| 1999 | -29.70% | -171.21% | 0.11x | 1.58x | $-450.93K |
| 2000 | -13.39% | -1704.65% | 0.01x | 1.10x | $-535.92K |
| 2014 | -2536.19% | -37040.83% | 0.03x | 2.26x | $-1.40 Million |
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-29.56K |
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | $-21.01K |
| 2021 | 0.00% | 0.00% | 0.00x | 0.00x | $-332.00K |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | $-18.49K |
| 2023 | -63.82% | 0.00% | 0.00x | 3.26x | $-13.28K |
| 2024 | -131.53% | 0.00% | 0.00x | 7.56x | $-10.99K |
Industry Comparison
This section compares Alternaturals Inc's net assets metrics with peer companies in the Shell Companies industry.
Industry Context
- Industry: Shell Companies
- Average net assets among peers: $36,677,338
- Average return on equity (ROE) among peers: -64.57%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Alternaturals Inc (ANAS) | $3.27K | -19.37% | 16.97x | $59.19 |
| Artius II Acquisition Inc. Class A Ordinary Shares (AACB) | $-60.27K | 0.00% | 0.00x | $198.37 Million |
| Artius II Acquisition Inc. Units (AACBU) | $-60.27K | 0.00% | 0.00x | $205.28 Million |
| Ares Acquisition Corporation II (AACT-UN) | $931.34 Million | 0.00% | 0.08x | $399.77 Million |
| AA Mission Acquisition Corp. (AAM-UN) | $-559.90 Million | 0.00% | 0.00x | $349.76 Million |
| Global Acquisitions Corporation (AASP) | $3.80 Million | -5.26% | 0.34x | $15.42 Million |
| ABV Consulting Inc (ABVN) | $8.75K | -623.31% | 2.50x | $461.96K |
| Atlantic Coastal Acquisition Corp II (ACAB) | $-8.52 Million | 0.00% | 0.00x | $2.44 Million |
| Annabidiol Corp (ACBD) | $-501.57K | 0.00% | 0.00x | $13.62K |
| ACRO Biomedical Co Ltd (ACBM) | $685.87K | -17.12% | 0.46x | $30.04K |
| Huaizhong Health Group Inc (ADAD) | $-19.47K | 0.00% | 0.00x | $3.15K |